TFRC and renal cell carcinoma: In subsequent in vitro studies using a human RCC preclinical platform to determine the therapeutic potential of ART, ART exhibited remarkably selective, dose-dependent cytotoxicity in the micromolar range against RCC cell lines with elevated levels of TfR1 (Caki-1, 786-O, and SN12C-GFP-SRLu2) (Figure 3A), strengthening the potential of TfR1 as a companion diagnostic biomarker for ART in RCC.